北陆药业：控股子公司碘美普尔化学原料药获批上市

Core Viewpoint - Northland Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Iopamidol, a contrast agent used in medical imaging [1] Company Summary - Northland Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, is now authorized to market Iopamidol, which is a raw material for the Iopamidol injection [1] - Iopamidol is characterized as a low-osmolar, non-ionic water-soluble contrast agent, making it suitable for various imaging procedures [1] Industry Summary - Iopamidol is widely used in CT enhancement imaging and vascular imaging, providing a safer alternative to traditional high-osmolar contrast agents [1] - The agent is particularly beneficial for patients with renal impairment and those at high risk, due to its lower burden on the kidneys and cardiovascular system [1] - Its favorable imaging effects and reduced side effects have made Iopamidol a preferred choice in clinical settings [1]